RayKnowChina Research Map
Shortlist

Blood disorders

Multiple myeloma

多发性骨髓瘤Myeloma

A cancer of mature plasma cells that make a single abnormal antibody. Typical features are bone damage, bone pain and fractures, often with anaemia, high blood calcium and kidney problems.

Definition adapted from MeSH (US National Library of Medicine)

hospitals in mainland China
175

with a paper from 2016–2025 or a registered study

cities
59

where those hospitals are

open trials in China
181

ClinicalTrials.gov, 8 Nov 2026

Mainland China accounts for 22% of the world's English-language research papers on multiple myeloma, 2021–2025 (14% in 2016–2020), and 12% of the world's registered trials on it have a site in China.

Research activity in public records, not a rating of care and not medical advice. How the numbers are made

175 hospitals in 59 cities

Order: papers led on multiple myeloma, 2021–2025, then A–Z. Research activity, not a rating of care.

A hospital is listed when it led at least 3 papers or 1 trial on multiple myeloma, or was a site in 3 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions

A square is a city. Its size and number are hospitals listed for this disease, not the amount of research. Choose one to show that city in the hospital list and the trial list.

Cities with the most listed hospitals

  1. Shanghai15
  2. Beijing14
  3. Guangzhou14
  4. Hangzhou9
  5. Jinan7
  6. Nanjing7
  7. Chongqing5
  8. Shenzhen5
  9. Tianjin5
  10. Changsha4

Each opens multiple myeloma in that city. 49 more cities are in the menu below.

  1. 59 papers led
    No open trial led
  2. First Affiliated Hospital, Zhejiang University

    浙江大学医学院附属第一医院Hangzhou

    55 papers led
  3. 52 papers led
    No open trial led
  4. Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC

    中国医学科学院血液病医院(血液学研究所)Tianjin

    47 papers led
  5. 37 papers led
  6. Union Hospital

    华中科技大学同济医学院附属协和医院Wuhan

    30 papers led
  7. 27 papers led
  8. 27 papers led
  9. 27 papers led
  10. Changzheng Hospital

    海军军医大学第二附属医院(长征医院)Shanghai

    26 papers led
  11. Jiangsu Province Hospital

    江苏省人民医院(南医大一附院)Nanjing

    24 papers led
  12. Renji Hospital

    上海交通大学医学院附属仁济医院Shanghai

    24 papers led
  13. Zhongshan Hospital, Fudan University

    复旦大学附属中山医院Shanghai

    23 papers led
  14. Ruijin Hospital

    上海交通大学医学院附属瑞金医院Shanghai

    22 papers led
    No open trial led
  15. 19 papers led
  16. Third Xiangya Hospital

    中南大学湘雅三医院Changsha

    19 papers led
    No open trial led
  17. Tongji Hospital

    华中科技大学同济医学院附属同济医院WuhanInternational Medical Department

    19 papers led
  18. 18 papers led
    No open trial led
  19. Henan Cancer Hospital

    河南省肿瘤医院Zhengzhou

    18 papers led
    No open trial led
  20. 17 papers led
  21. 17 papers led
    No open trial led
  22. 17 papers led
  23. 17 papers led
    No open trial led
  24. 16 papers led
  25. 16 papers led
    No open trial led
  26. 16 papers led
    No open trial led
  27. 15 papers led
  28. 15 papers led
    No open trial led
  29. Second Xiangya Hospital

    中南大学湘雅二医院Changsha

    14 papers led
    No open trial led
  30. 13 papers led
    No open trial led
  31. 13 papers led
    No open trial led
  32. 12 papers led
    No open trial led
  33. 12 papers led
  34. 11 papers led
    No open trial led
  35. 10 papers led
    No open trial led
  36. 10 papers led
    No open trial led
  37. 10 papers led
    No open trial led
  38. 10 papers led
  39. 10 papers led
    No open trial led
  40. 9 papers led
    No open trial led
  41. 8 papers led
    No open trial led
  42. 8 papers led
    No open trial led
  43. 8 papers led
  44. 8 papers led
    No open trial led
  45. Tianjin First Central Hospital

    天津市第一中心医院Tianjin

    8 papers led
    No open trial led
  46. Xiangya Hospital

    中南大学湘雅医院Changsha

    8 papers led
    No open trial led
  47. 7 papers led
  48. 7 papers led
    No open trial led
  49. 7 papers led
    No open trial led
  50. 7 papers led
    No open trial led
  51. Shengjing Hospital of China Medical University

    中国医科大学附属盛京医院Shenyang

    7 papers led
    No open trial led
  52. Zhabei Central Hospital

    上海市静安区闸北中心医院Shanghai

    7 papers led
    No open trial led
  53. 6 papers led
    No open trial led
  54. Beijing Tongren Hospital

    首都医科大学附属北京同仁医院Beijing

    6 papers led
    No open trial led
  55. 6 papers led
    No open trial led
  56. Fujian Medical University Union Hospital

    福建医科大学附属协和医院Fuzhou

    6 papers led
    No open trial led
  57. Harbin Medical University Cancer Hospital

    哈尔滨医科大学附属肿瘤医院Harbin

    6 papers led
    No open trial led
  58. Huai'an First People's Hospital

    淮安市第一人民医院Huai'an

    6 papers led
    No open trial led
  59. 6 papers led
    No open trial led
  60. 6 papers led
    No open trial led
  61. 6 papers led
    No open trial led
  62. Chinese PLA General Hospital

    中国人民解放军总医院Beijing

    5 papers led
  63. 5 papers led
    No open trial led
  64. 5 papers led
    No open trial led
  65. 5 papers led
    No open trial led
  66. Hangzhou First People's Hospital

    杭州市第一人民医院Hangzhou

    5 papers led
    No open trial led
  67. 5 papers led
    No open trial led
  68. 5 papers led
    No open trial led
  69. 5 papers led
    No open trial led
  70. 5 papers led
  71. Shanghai Tenth People's Hospital

    上海市第十人民医院Shanghai

    5 papers led
    No open trial led
  72. Xinqiao Hospital, Army Medical University

    陆军军医大学第二附属医院(新桥医院)Chongqing

    5 papers led
    No open trial led
  73. 4 papers led
    No open trial led
  74. 4 papers led
    No open trial led
  75. 4 papers led
    No open trial led
  76. 4 papers led
    No open trial led
  77. China-Japan Union Hospital, Jilin University

    吉林大学白求恩第三医院(中日联谊医院)Changchun

    4 papers led
    No open trial led
  78. 4 papers led
    No open trial led
  79. 4 papers led
    No open trial led
  80. 4 papers led
    No open trial led
  81. 4 papers led
    No open trial led
  82. 4 papers led
    No open trial led
  83. First Hospital of China Medical University

    中国医科大学附属第一医院Shenyang

    4 papers led
    No open trial led
  84. 4 papers led
    No open trial led
  85. 4 papers led
    No open trial led
  86. Jinling Hospital

    东部战区总医院(金陵医院)Nanjing

    4 papers led
  87. 4 papers led
    No open trial led
  88. 4 papers led
    No open trial led
  89. 4 papers led
    No open trial led
  90. Sir Run Run Shaw Hospital

    浙江大学医学院附属邵逸夫医院Hangzhou

    4 papers led
    No open trial led
  91. 4 papers led
    No open trial led
  92. Zhongda Hospital, Southeast University

    东南大学附属中大医院Nanjing

    4 papers led
    No open trial led
  93. 3 papers led
    No open trial led
  94. 3 papers led
  95. 3 papers led
    No open trial led
  96. 3 papers led
    No open trial led
  97. 3 papers led
    No open trial led
  98. 3 papers led
    No open trial led
  99. Dazhou Central Hospital

    达州市中心医院Dazhou

    3 papers led
    No open trial led
  100. 3 papers led
  101. 3 papers led
    No open trial led
  102. 3 papers led
    No open trial led
  103. 3 papers led
    No open trial led
  104. 3 papers led
    No open trial led
  105. 3 papers led
    No open trial led
  106. 3 papers led
  107. Nanfang Hospital

    南方医科大学南方医院Guangzhou

    3 papers led
    No open trial led
  108. Ningbo Hangzhou Bay Hospital

    宁波市杭州湾医院Ningbo

    3 papers led
    No open trial led
  109. 3 papers led
    No open trial led
  110. 3 papers led
  111. 3 papers led
    No open trial led
  112. 3 papers led
    No open trial led
  113. 3 papers led
    No open trial led
  114. Shanghai Fourth People's Hospital

    同济大学附属上海市第四人民医院Shanghai

    3 papers led
  115. 3 papers led
    No open trial led
  116. 3 papers led
  117. 3 papers led
    No open trial led
  118. Yueyang Hospital, Shanghai University of Traditional Chinese Medicine

    上海中医药大学附属岳阳中西医结合医院Shanghai

    3 papers led
    No open trial led
  119. 2 papers led
    No open trial led
  120. 2 papers led
  121. 2 papers led
    No open trial led
  122. 2 papers led
    No open trial led
  123. 2 papers led
    No open trial led
  124. Chongqing University Cancer Hospital

    重庆大学附属肿瘤医院Chongqing

    2 papers led
    No open trial led
  125. 2 papers led
    No open trial led
  126. First Affiliated Hospital of Shandong First Medical University

    山东第一医科大学第一附属医院(山东省千佛山医院)Jinan

    2 papers led
    No open trial led
  127. First Affiliated Hospital of USTC

    中国科学技术大学附属第一医院(安徽省立医院)Hefei

    2 papers led
  128. First Affiliated Hospital of Zhejiang Chinese Medical University

    浙江中医药大学附属第一医院(浙江省中医院)Hangzhou

    2 papers led
    No open trial led
  129. 2 papers led
    No open trial led
  130. Hainan General Hospital / Hainan Medical University hospitals

    海南医学院附属医院/海南省人民医院Haikou

    2 papers led
    No open trial led
  131. 2 papers led
    No open trial led
  132. Linyi People's Hospital

    临沂市人民医院Linyi

    2 papers led
    No open trial led
  133. 2 papers led
    No open trial led
  134. 2 papers led
    No open trial led
  135. 2 papers led
    No open trial led
  136. 2 papers led
    No open trial led
  137. 2 papers led
    No open trial led
  138. Shanghai General Hospital

    上海市第一人民医院Shanghai

    2 papers led
    No open trial led
  139. 2 papers led
    No open trial led
  140. Taizhou Hospital, Wenzhou Medical University

    温州医科大学附属台州医院Taizhou

    2 papers led
    No open trial led
  141. 2 papers led
    No open trial led
  142. Tongji Hospital

    同济大学附属同济医院Shanghai

    2 papers led
  143. Xijing Hospital

    空军军医大学西京医院Xi'an

    2 papers led
    No open trial led
  144. Xinhua Hospital

    上海交通大学医学院附属新华医院Shanghai

    2 papers led
    No open trial led
  145. 2 papers led
    No open trial led
  146. Zhongshan Hospital, Xiamen University

    厦门大学附属中山医院Xiamen

    2 papers led
    No open trial led
  147. Zhujiang Hospital

    南方医科大学珠江医院Guangzhou

    2 papers led
  148. 1 paper led
    No open trial led
  149. 1 paper led
  150. 1 paper led
    No open trial led
  151. 1 paper led
    No open trial led
  152. Hebei Yanda Lu Daopei Hospital

    河北燕达陆道培医院Langfang

    1 paper led
    No open trial led
  153. Longgang District People's Hospital

    深圳市龙岗区人民医院Shenzhen

    1 paper led
    No open trial led
  154. 1 paper led
    No open trial led
  155. 1 paper led
    No open trial led
  156. Shanghai Sixth People's Hospital

    上海市第六人民医院Shanghai

    1 paper led
    No open trial led
  157. 1 paper led
    No open trial led
  158. Sun Yat-sen Memorial Hospital

    中山大学孙逸仙纪念医院Guangzhou

    1 paper led
    No open trial led
  159. 0 papers led
  160. 0 papers led
    No open trial led
  161. 0 papers led
    No open trial led
  162. Beijing Boren Hospital

    北京高博博仁医院Beijing

    0 papers led
    No open trial led
  163. 0 papers led
  164. 0 papers led
    No open trial led
  165. 0 papers led
    No open trial led
  166. 0 papers led
    No open trial led
  167. 0 papers led
    No open trial led
  168. Hunan Cancer Hospital

    湖南省肿瘤医院Changsha

    0 papers led
    No open trial led
  169. Shanxi Bethune Hospital

    山西白求恩医院Taiyuan

    0 papers led
  170. Shanxi Cancer Hospital

    山西省肿瘤医院Taiyuan

    0 papers led
    No open trial led
  171. 0 papers led
    No open trial led
  172. Southwest Hospital, Army Medical University

    陆军军医大学第一附属医院(西南医院)Chongqing

    0 papers led
    No open trial led
  173. Tongde Hospital

    浙江省立同德医院Hangzhou

    0 papers led
    No open trial led
  174. 0 papers led
    No open trial led
  175. 0 papers led
    No open trial led

By university or health system 57

Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.

  1. Peking Union Medical College / Chinese Academy of Medical Sciences

    北京协和医学院/中国医学科学院Beijing

    80 papers led
    4 hospitals
  2. Capital Medical University

    首都医科大学Beijing

    66 papers led
    6 hospitals
  3. Zhejiang University School of Medicine

    浙江大学医学院Hangzhou

    66 papers led
    5 hospitals
  4. Sichuan University (West China)

    四川大学华西Chengdu

    63 papers led
    4 hospitals
  5. Shanghai Jiao Tong University School of Medicine

    上海交通大学医学院Shanghai

    53 papers led
    6 hospitals
  6. Central South University (Xiangya)

    中南大学湘雅Changsha

    50 papers led
    4 hospitals
  7. Huazhong Univ. of Sci. & Tech. – Tongji Medical College

    华中科技大学同济医学院Wuhan

    50 papers led
    3 hospitals
  8. Peking University Health Science Center

    北京大学医学部Beijing

    50 papers led
    6 hospitals
  9. Sun Yat-sen University

    中山大学Guangzhou

    49 papers led
    6 hospitals
  10. Xuzhou Medical University

    徐州医科大学Xuzhou

    46 papers led
    3 hospitals
  11. Tianjin Medical University

    天津医科大学Tianjin

    41 papers led
    3 hospitals
  12. Nanjing Medical University

    南京医科大学Nanjing

    39 papers led
    6 hospitals
  13. Zhengzhou University

    郑州大学Zhengzhou

    39 papers led
    4 hospitals
  14. Soochow University

    苏州大学Suzhou

    38 papers led
    5 hospitals
  15. Fudan University

    复旦大学Shanghai

    37 papers led
    6 hospitals
  16. Naval Medical University

    海军军医大学Shanghai

    30 papers led
    2 hospitals
  17. Fujian Medical University

    福建医科大学Fuzhou

    28 papers led
    6 hospitals
  18. Shandong University

    山东大学Jinan

    28 papers led
    5 hospitals
  19. Xi'an Jiaotong University

    西安交通大学Xi'an

    28 papers led
    4 hospitals
  20. Jilin University

    吉林大学Changchun

    25 papers led
    4 hospitals
  21. Tongji University

    同济大学Shanghai

    24 papers led
    6 hospitals
  22. Nanjing University

    南京大学Nanjing

    21 papers led
    2 hospitals
  23. Anhui Medical University

    安徽医科大学Hefei

    20 papers led
    5 hospitals
  24. Harbin Medical University

    哈尔滨医科大学Harbin

    17 papers led
    5 hospitals
  25. 17 papers led
    3 hospitals
  26. Nanchang University

    南昌大学Nanchang

    16 papers led
    2 hospitals
  27. Nantong University

    南通大学Nantong

    16 papers led
    1 hospital
  28. Shandong First Medical University

    山东第一医科大学Jinan

    16 papers led
    5 hospitals
  29. Wenzhou Medical University

    温州医科大学Wenzhou

    15 papers led
    6 hospitals
  30. China Medical University (Shenyang)

    中国医科大学Shenyang

    12 papers led
    2 hospitals
  31. Guangzhou Medical University

    广州医科大学Guangzhou

    12 papers led
    5 hospitals
  32. Hebei Medical University

    河北医科大学Shijiazhuang

    12 papers led
    5 hospitals
  33. Wuhan University

    武汉大学Wuhan

    12 papers led
    1 hospital
  34. Xiamen University

    厦门大学Xiamen

    12 papers led
    2 hospitals
  35. Guangxi Medical University

    广西医科大学Nanning

    11 papers led
    1 hospital
  36. Jinan University

    暨南大学Guangzhou

    10 papers led
    3 hospitals
  37. Qingdao University

    青岛大学Qingdao

    10 papers led
    3 hospitals
  38. Southern Medical University

    南方医科大学Guangzhou

    10 papers led
    5 hospitals
  39. Southwest Medical University

    西南医科大学Luzhou

    10 papers led
    1 hospital
  40. Guizhou Medical University

    贵州医科大学Guiyang

    8 papers led
    1 hospital
  41. Chongqing Medical University

    重庆医科大学Chongqing

    7 papers led
    3 hospitals
  42. 6 papers led
    2 hospitals
  43. Army Medical University

    陆军军医大学Chongqing

    5 papers led
    1 hospital
  44. Bengbu Medical University

    蚌埠医科大学Bengbu

    5 papers led
    1 hospital
  45. Chinese PLA General Hospital

    中国人民解放军总医院Beijing

    5 papers led
    1 hospital
  46. Chongqing University

    重庆大学Chongqing

    5 papers led
    4 hospitals
  47. Shenzhen University

    深圳大学Shenzhen

    5 papers led
    3 hospitals
  48. Xinjiang Medical University

    新疆医科大学Urumqi

    5 papers led
    2 hospitals
  49. Guangdong Medical University

    广东医科大学Zhanjiang

    4 papers led
    1 hospital
  50. Ningxia Medical University

    宁夏医科大学Yinchuan

    4 papers led
    1 hospital
  51. Air Force Medical University

    空军军医大学Xi'an

    3 papers led
    2 hospitals
  52. Guilin Medical University

    桂林医学院Guilin

    3 papers led
    1 hospital
  53. Shantou University Medical College

    汕头大学医学院Shantou

    2 papers led
    1 hospital
  54. University of Chinese Academy of Sciences

    中国科学院大学Beijing

    2 papers led
    1 hospital
  55. 2 papers led
    1 hospital
  56. Jiangnan University

    江南大学Wuxi

    1 paper led
    1 hospital
  57. Kunming Medical University

    昆明医科大学Kunming

    1 paper led
    1 hospital

181

open trials on multiple myeloma in China

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 8 Nov 2026, with at least one listed hospital as lead sponsor or site. 118 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.

Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial

What the phases mean (US National Cancer Institute)

  1. Recruiting
    A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
    Phase
    Phase 1
    Started
    2026-03
    Registry
    NCT07255898

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu

  2. Recruiting
    A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-02
    Registry
    NCT07258511

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanjing, Nanning, Wenzhou, Wuhan, Xi'an

  3. Recruiting
    IASO206 in Patients With Relapsed/Refractory Multiple Myeloma
    Phase
    Early phase 1
    Started
    2026-01
    Registry
    NCT07322159

    Age 18 years to 75 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  4. Recruiting
    A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
    Phase
    Phase 1
    Started
    2026-02
    Registry
    NCT07409246

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Tianjin

  5. Recruiting
    MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07409454

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  6. Recruiting
    A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.
    Phase
    Early phase 1
    Started
    2026-03
    Registry
    NCT07429721

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  7. Recruiting
    A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-03
    Registry
    NCT07452198

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  8. Recruiting
    To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2026-04
    Registry
    NCT07454187

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Suzhou, Xi'an, Zhengzhou

  9. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  10. Recruiting
    A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-06
    Registry
    NCT07490613

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteSuzhou

  11. Recruiting
    A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
    Phase
    Early phase 1
    Started
    2026-04
    Registry
    NCT07493135

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  12. Recruiting
    Predicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study
    Phase
    Not given
    Started
    2026-01
    Registry
    NCT07514052

    Age 18 years to Not stated (registered criteria)

    Led by Shanxi Bethune HospitalTaiyuan

  13. Recruiting
    A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07518186

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Hangzhou, Nanchang, Nanjing, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an

  14. Recruiting
    Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Registry
    NCT07523555

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  15. Recruiting
    Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-03
    Registry
    NCT07529782

    Age Not stated to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Jinan, Suzhou, Tianjin

  16. Recruiting
    Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07555938

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesGuangzhou, Hangzhou, Jinan, Kunming, Nanjing, Qingdao, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan

  17. Recruiting
    A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-01
    Registry
    NCT07579234

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  18. Recruiting
    CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07585760

    Age 18 years to 80 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  19. Recruiting
    Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
    Phase
    Phase 1
    Started
    2026-09
    Registry
    NCT07620275

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General Hospital; 2 listed hospitals as study sitesBeijing, Tianjin

  20. Recruiting
    A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07623798

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  21. Recruiting
    A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07638683

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  22. Recruiting
    A Clinical Study of SHR-5421 in Patients With Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-07
    Registry
    NCT07652281

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  23. Recruiting
    CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07652905

    Age 18 years to 75 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  24. Recruiting
    GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders
    Phase
    Phase 1
    Started
    2026-06
    Registry
    NCT07660939

    Age 18 years to 80 years (registered criteria)

    Led by Peking University First HospitalBeijing

  25. Recruiting
    Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
    Phase
    Not given
    Started
    2026-06
    Registry
    NCT07663253

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 9 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Kunming, Nanning, Nantong, Shanghai, Wuhan, Xi'an, Zhengzhou

  26. Recruiting
    A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2026-09
    Registry
    NCT07760454

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Suzhou

  27. Recruiting
    CD38 Targeted -PET/ CT for Multiple Myeloma
    Phase
    N/A
    Started
    2026-07
    Registry
    NCT07782944

    Age 18 years to Not stated (registered criteria)

    Led by Affiliated Hospital of Guilin Medical UniversityGuilin

  28. Recruiting
    Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers
    Phase
    Phase 1
    Started
    2026-09
    Registry
    NCT07914556

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  29. Recruiting
    Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT06514508

    Age 18 years to 78 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  30. Recruiting
    A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma
    Phase
    Early phase 1
    Started
    2025-04
    Registry
    NCT06717113

    Age 18 years to 80 years (registered criteria)

    Led by Peking University First HospitalBeijing

  31. Recruiting
    A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
    Phase
    Early phase 1
    Started
    2025-07
    Registry
    NCT06730256

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  32. Recruiting
    Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
    Phase
    Phase 1
    Started
    2025-01
    Registry
    NCT06758713

    Age 18 years to 75 years (registered criteria)

    Led by Third Affiliated Hospital of Southern Medical UniversityGuangzhou

  33. Recruiting
    A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma
    Phase
    Early phase 1
    Started
    2025-01
    Registry
    NCT06791681

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  34. Recruiting
    BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma
    Phase
    Phase 2
    Started
    2025-02
    Registry
    NCT06793449

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  35. Recruiting
    Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease
    Phase
    N/A
    Started
    2025-04
    Registry
    NCT06793475

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  36. Recruiting
    KPD Consolidation After ASCT in NDMM Patients
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Registry
    NCT06879379

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's Hospital; 1 listed hospital as study siteBeijing, Shanghai

  37. Recruiting
    BCMA CAR-T for Dynamic High-risk Multiple Myeloma
    Phase
    Phase 2
    Started
    2025-03
    Registry
    NCT06880393

    Age 18 years to 75 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  38. Recruiting
    GR1803 Injection in Patients With RRMM
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06952075

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  39. Recruiting
    Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
    Phase
    N/A
    Started
    2025-04
    Registry
    NCT06961669

    Age 3 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  40. Recruiting
    A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
    Phase
    Early phase 1
    Started
    2025-05
    Registry
    NCT06976437

    Age 18 years to Not stated (registered criteria)

    Led by Affiliated Hospital of Jiangsu UniversityChangzhou

  41. Recruiting
    A Study of CT0596 in Plasma Cell Leukemia
    Phase
    Early phase 1
    Started
    2025-06
    Registry
    NCT06988059

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  42. Recruiting
    A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2025-10
    Registry
    NCT06988488

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Fourth People's HospitalShanghai

  43. Recruiting
    Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
    Phase
    Phase 1
    Started
    2025-05
    Registry
    NCT07003555

    Age 18 years to 75 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  44. Recruiting
    Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
    Phase
    Phase 1
    Started
    2025-05
    Registry
    NCT07003568

    Age 18 years to 75 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  45. Recruiting
    Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07018050

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  46. Recruiting
    Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research
    Phase
    Early phase 1
    Started
    2025-06
    Registry
    NCT07085559

    Age 19 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  47. Recruiting
    LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
    Phase
    N/A
    Started
    2025-09
    Registry
    NCT07100067

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Tianjin, Wuhan

  48. Recruiting
    An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
    Phase
    Early phase 1
    Started
    2025-09
    Registry
    NCT07101705

    Age 18 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  49. Recruiting
    A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07106671

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  50. Recruiting
    ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07106684

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  51. Recruiting
    ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07106710

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  52. Recruiting
    MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07106736

    Age 18 years to 75 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  53. Recruiting
    Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
    Phase
    Phase 1/Phase 2
    Started
    2025-03
    Registry
    NCT07109323

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  54. Recruiting
    Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients
    Phase
    Phase 1/Phase 2
    Started
    2025-03
    Registry
    NCT07169500

    Age 18 years to 50 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  55. Recruiting
    A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
    Phase
    Phase 1
    Started
    2025-12
    Registry
    NCT07179679

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChengde, Chongqing, Guangzhou, Nanchang, Nanchong, Nanjing, Shanghai, Suzhou, Xi'an

  56. Recruiting
    Universal CAR-T Cell Therapy for MM
    Phase
    N/A
    Started
    2025-04
    Registry
    NCT07248176

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalShanghai

  57. Recruiting
    CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma
    Phase
    Early phase 1
    Started
    2025-03
    Registry
    NCT07249073

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  58. Recruiting
    A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
    Phase
    Early phase 1
    Started
    2025-12
    Registry
    NCT07294625

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province Hospital; 4 listed hospitals as study sitesNanjing, Shanghai, Xi'an, Xuzhou, Zhengzhou

  59. Recruiting
    Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients
    Phase
    Not given
    Started
    2025-07
    Registry
    NCT07296627

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  60. Recruiting
    A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07297329

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  61. Recruiting
    Randomised Controlled Trial of Artificial Intelligence-assisted Health Education
    Phase
    N/A
    Started
    2025-06
    Registry
    NCT07305337

    Age 18 years to 90 years (registered criteria)

    Led by Zhongnan Hospital of Wuhan UniversityWuhan

  62. Recruiting
    A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07312188

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  63. Recruiting
    68Ga-BCMA PET/CT in Multiple Myeloma
    Phase
    Phase 2/Phase 3
    Started
    2025-12
    Registry
    NCT07319897

    Age 18 years to 80 years (registered criteria)

    Led by Peking University First Hospital; 2 listed hospitals as study sitesBeijing, Changchun, Shijiazhuang

  64. Recruiting
    Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma
    Phase
    N/A
    Started
    2025-11
    Registry
    NCT07359014

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  65. Recruiting
    Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2025-10
    Registry
    NCT07369895

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  66. Recruiting
    Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen
    Phase
    Phase 3
    Started
    2025-10
    Registry
    NCT07413809

    Age 18 years to 65 years (registered criteria)

    Led by Affiliated People's Hospital of Ningbo UniversityNingbo

  67. Recruiting
    Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07489534

    Age 14 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  68. Recruiting
    Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
    Phase
    Not given
    Started
    2025-11
    Registry
    NCT07497165

    Age 18 years to 75 years (registered criteria)

    Led by Shanxi Bethune HospitalTaiyuan

  69. Recruiting
    IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07509086

    Age 18 years to 80 years (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  70. Recruiting
    Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2025-07
    Registry
    NCT07652138

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  71. Recruiting
    Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07763054

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated Hospital of Central South UniversityHaikou

  72. Recruiting
    A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06083207

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Nanjing, Nanning, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an, Xuzhou

  73. Recruiting
    The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial
    Phase
    Not given
    Started
    2024-04
    Registry
    NCT06228794

    Age 18 years to 80 years (registered criteria)

    Led by Union HospitalWuhan

  74. Recruiting
    A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
    Phase
    Phase 1/Phase 2
    Started
    2024-02
    Registry
    NCT06232096

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  75. Recruiting
    UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
    Phase
    N/A
    Started
    2024-04
    Registry
    NCT06279026

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteSuzhou

  76. Recruiting
    Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2024-05
    Registry
    NCT06375044

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Nanjing, Tianjin, Zhengzhou

  77. Recruiting
    PET Imaging Study of 68Ga-NB381 in Multiple Myeloma
    Phase
    Early phase 1
    Started
    2024-04
    Registry
    NCT06385652

    Age 18 years to 90 years (registered criteria)

    Led by Peking University First HospitalBeijing

  78. Recruiting
    Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma
    Phase
    Early phase 1
    Started
    2024-06
    Registry
    NCT06407947

    Age 18 years to Not stated (registered criteria)

    Led by Changzheng HospitalShanghai

  79. Recruiting
    Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
    Phase
    Phase 4
    Started
    2024-06
    Registry
    NCT06409702

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  80. Recruiting
    A Clinical Study of SHR-9539 in Patients With Multiple Myeloma
    Phase
    Phase 1
    Started
    2024-08
    Registry
    NCT06484777

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu

  81. Recruiting
    Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2024-03
    Registry
    NCT06484829

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu

  82. Recruiting
    A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma
    Phase
    Not given
    Started
    2024-05
    Registry
    NCT06497738

    Age 65 years to Not stated (registered criteria)

    Led by Jiangsu Province Hospital; 2 listed hospitals as study sitesChangzhou, Nanjing, Nantong

  83. Recruiting
    A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
    Phase
    Phase 3
    Started
    2024-06
    Registry
    NCT06508983

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Suzhou, Tianjin, Wuhan, Xi'an, Zhengzhou

  84. Recruiting
    Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
    Phase
    Phase 3
    Started
    2024-08
    Registry
    NCT06520176

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated People's Hospital of Ningbo University; 6 listed hospitals as study sitesHangzhou, Ningbo, Taizhou, Wenzhou

  85. Recruiting
    Intestinal Flora and Immunity in Monoclonal Gammopathy Patients
    Phase
    Not given
    Started
    2024-05
    Registry
    NCT06539832

    Age 45 years to Not stated (registered criteria)

    Led by Zhujiang HospitalGuangzhou

  86. Recruiting
    A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2024-06
    Registry
    NCT06574568

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Jinan, Taiyuan, Zhengzhou

  87. Recruiting
    Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 2
    Started
    2024-09
    Registry
    NCT06581640

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  88. Recruiting
    A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Phase
    Phase 1
    Started
    2024-10
    Registry
    NCT06644118

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  89. Recruiting
    Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients
    Phase
    Not given
    Started
    2024-09
    Registry
    NCT06682156

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  90. Recruiting
    Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT06690593

    Age 45 years to Not stated (registered criteria)

    Led by Zhujiang HospitalGuangzhou

  91. Recruiting
    Risk Stratification and MRD-driven Maintenance for MM After ASCT
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT06697483

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's Hospital; 2 listed hospitals as study sitesBeijing, Harbin

  92. Recruiting
    A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma
    Phase
    Phase 1
    Started
    2024-11
    Registry
    NCT06700395

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Shanghai

  93. Recruiting
    a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
    Phase
    Early phase 1
    Started
    2024-12
    Registry
    NCT06718270

    Age 18 years to Not stated (registered criteria)

    Led by Changzheng HospitalShanghai

  94. Recruiting
    BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT06745687

    Age 18 years to 78 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  95. Recruiting
    The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Registry
    NCT06911710

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University General HospitalTianjin

  96. Recruiting
    A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma
    Phase
    Early phase 1
    Started
    2024-09
    Registry
    NCT06999031

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Nanchang UniversityNanchang

  97. Recruiting
    Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT07028970

    Age not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Tianjin, Wuhan, Zhengzhou

  98. Recruiting
    Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma
    Phase
    Phase 4
    Started
    2024-02
    Registry
    NCT07907211

    Age 18 years to 70 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  99. Recruiting
    Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2023-02
    Registry
    NCT05565807

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou

  100. Recruiting
    Screening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS Analysis
    Phase
    Not given
    Started
    2023-01
    Registry
    NCT05686447

    Age not stated (registered criteria)

    Led by Zhujiang HospitalGuangzhou

  101. Recruiting
    A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
    Phase
    Phase 1
    Started
    2023-03
    Registry
    NCT05759793

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  102. Recruiting
    The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study
    Phase
    Not given
    Started
    2023-07
    Registry
    NCT05965115

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  103. Recruiting
    Helical Tomotherapy in Multiple Myeloma
    Phase
    N/A
    Started
    2023-06
    Registry
    NCT05970198

    Age 18 years to 75 years (registered criteria)

    Led by Zhongnan Hospital of Wuhan UniversityWuhan

  104. Recruiting
    A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia
    Phase
    Phase 2
    Started
    2023-08
    Registry
    NCT05979363

    Age 18 years to 75 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  105. Recruiting
    Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple Myeloma
    Phase
    Not given
    Started
    2023-11
    Registry
    NCT06039735

    Age 18 years to 70 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  106. Recruiting
    To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
    Phase
    Early phase 1
    Started
    2023-07
    Registry
    NCT06045091

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  107. Recruiting
    A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2023-10
    Registry
    NCT06049290

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Guiyang, Haikou, Hangzhou, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Suzhou, Taiyuan, Wenzhou, Wuhan, Wuhu, Xi'an, Xiamen, Zhengzhou

  108. Recruiting
    Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
    Phase
    Phase 4
    Started
    2023-10
    Registry
    NCT06057402

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Jinan

  109. Recruiting
    Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
    Phase
    Phase 2
    Started
    2023-10
    Registry
    NCT06140966

    Age 18 years to 70 years (registered criteria)

    Led by Union HospitalWuhan

  110. Recruiting
    DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
    Phase
    Phase 2
    Started
    2023-12
    Registry
    NCT06158269

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  111. Recruiting
    All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
    Phase
    Phase 2
    Started
    2023-11
    Registry
    NCT06158412

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  112. Recruiting
    OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
    Phase
    Phase 1/Phase 2
    Started
    2023-10
    Registry
    NCT06182696

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Nanjing, Shanghai, Wuhan

  113. Recruiting
    Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
    Phase
    Phase 1/Phase 2
    Started
    2023-12
    Registry
    NCT06196255

    Age 18 years to 70 years (registered criteria)

    Led by Affiliated Hospital of Xuzhou Medical UniversityXuzhou

  114. Recruiting
    Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2023-11
    Registry
    NCT06246162

    Age 18 years to 70 years (registered criteria)

    Led by Affiliated Hospital of Nantong UniversityNantong

  115. Recruiting
    Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma
    Phase
    Not given
    Started
    2023-06
    Registry
    NCT06252792

    Age 18 years to Not stated (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  116. Recruiting
    Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not
    Phase
    Not given
    Started
    2023-12
    Registry
    NCT06463717

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  117. Recruiting
    Longitudinal Data Registry of Plasma Cell Dyscrasia
    Phase
    Not given
    Started
    2023-03
    Registry
    NCT06760052

    Age 19 years to 99 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  118. Recruiting
    A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors
    Phase
    N/A
    Started
    2023-12
    Registry
    NCT06783816

    Age not stated (registered criteria)

    Led by Shanxi Bethune HospitalTaiyuan

  119. Recruiting
    High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)
    Phase
    Not given
    Started
    2023-09
    Registry
    NCT07205523

    Age not stated (registered criteria)

    Led by Affiliated Hospital of Qinghai UniversityXining

  120. Recruiting
    APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma
    Phase
    Early phase 1
    Started
    2022-05
    Registry
    NCT04657861

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  121. Recruiting
    A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
    Phase
    Phase 4
    Started
    2022-03
    Registry
    NCT05201781

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an

  122. Recruiting
    A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
    Phase
    Phase 1
    Started
    2022-03
    Registry
    NCT05219721

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  123. Recruiting
    Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
    Phase
    Phase 3
    Started
    2022-09
    Registry
    NCT05243797

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Hangzhou, Jinan, Shanghai, Shenyang, Tianjin, Wenzhou, Wuhan, Zhengzhou

  124. Recruiting
    Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
    Phase
    Phase 2
    Started
    2022-04
    Registry
    NCT05294055

    Age 18 years to 65 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 6 listed hospitals as study sitesBeijing, Hefei, Jinan, Tianjin, Zhengzhou

  125. Recruiting
    A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2022-08
    Registry
    NCT05299424

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  126. Recruiting
    A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2022-11
    Registry
    NCT05521802

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  127. Recruiting
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2022-10
    Registry
    NCT05552222

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  128. Recruiting
    Human BCMA Targeted T Cells Injection(BCMA CAR-T)for Subjects With R/R MM
    Phase
    Phase 2
    Started
    2022-07
    Registry
    NCT05594797

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Wenzhou

  129. Recruiting
    The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
    Phase
    N/A
    Started
    2022-09
    Registry
    NCT05618041

    Age 14 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTaiyuan

  130. Recruiting
    A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05623020

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan

  131. Recruiting
    ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
    Phase
    Phase 1/Phase 2
    Started
    2022-07
    Registry
    NCT05632380

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  132. Recruiting
    Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
    Phase
    Phase 4
    Started
    2022-07
    Registry
    NCT05722405

    Age 18 years to 80 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  133. Recruiting
    A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 2
    Started
    2021-02
    Registry
    NCT04634552

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Suzhou, Tianjin, Xi'an

  134. Recruiting
    CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
    Phase
    Early phase 1
    Started
    2021-11
    Registry
    NCT04662294

    Age not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  135. Recruiting
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Registry
    NCT04973605

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chongqing, Fuzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou

  136. Recruiting
    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
    Phase
    Phase 3
    Started
    2021-10
    Registry
    NCT05020236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xuzhou, Zhengzhou

  137. Recruiting
    A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
    Phase
    Not given
    Started
    2021-07
    Registry
    NCT05283993

    Age not stated (registered criteria)

    Led by Peking University First HospitalBeijing

  138. Recruiting
    Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMM
    Phase
    Not given
    Started
    2021-09
    Registry
    NCT06099912

    Age 65 years to Not stated (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  139. Recruiting
    Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
    Phase
    Early phase 1
    Started
    2020-08
    Registry
    NCT04504526

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou

  140. Recruiting
    National Longitudinal Cohort of Hematological Diseases
    Phase
    Not given
    Started
    2020-12
    Registry
    NCT04645199

    Age not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  141. Recruiting
    Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients
    Phase
    Phase 1/Phase 2
    Started
    2019-07
    Registry
    NCT04025450

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  142. Recruiting
    BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
    Phase
    Phase 1
    Started
    2019-07
    Registry
    NCT04162353

    Age not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  143. Recruiting
    Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2016-09
    Registry
    NCT03196414

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  144. Not yet recruiting
    Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 2
    Started
    2027-12
    Registry
    NCT07695740

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  145. Not yet recruiting
    Isa-VRD in TIE HRMM
    Phase
    Phase 4
    Started
    2026-01
    Registry
    NCT07334535

    Age 18 years to 80 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  146. Not yet recruiting
    Application Study of 68Ga-NOTA-BCMA Nanoantibody Imaging in Multiple Myeloma
    Phase
    N/A
    Started
    2026-02
    Registry
    NCT07353554

    Age 18 years to 85 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  147. Not yet recruiting
    A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment
    Phase
    N/A
    Started
    2026-02
    Registry
    NCT07376720

    Age 18 years to 78 years (registered criteria)

    Led by Tongji HospitalWuhan

  148. Not yet recruiting
    A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)
    Phase
    Early phase 1
    Started
    2026-01
    Registry
    NCT07399444

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 4 listed hospitals as study sitesNanchang, Tianjin, Wuhan, Xuzhou, Zhengzhou

  149. Not yet recruiting
    A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.
    Phase
    Early phase 1
    Started
    2026-04
    Registry
    NCT07539233

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  150. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

  151. Not yet recruiting
    Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma
    Phase
    Early phase 1
    Started
    2026-07
    Registry
    NCT07628595

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  152. Not yet recruiting
    Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification
    Phase
    Phase 1/Phase 2
    Started
    2026-08
    Registry
    NCT07687004

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  153. Not yet recruiting
    A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen
    Phase
    Phase 4
    Started
    2026-07
    Registry
    NCT07709884

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  154. Not yet recruiting
    A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-07
    Registry
    NCT07726160

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  155. Not yet recruiting
    A Open-Label Phase in Participants With Multiple Myeloma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07764861

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  156. Not yet recruiting
    HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07811986

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  157. Not yet recruiting
    CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07830485

    Age 18 years to 75 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  158. Not yet recruiting
    QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
    Phase
    Phase 2
    Started
    2026-12
    Registry
    NCT07903636

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  159. Not yet recruiting
    Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-12
    Registry
    NCT07910903

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  160. Not yet recruiting
    Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
    Phase
    Phase 3
    Started
    2025-09
    Registry
    NCT06580223

    Age 18 years to 90 years (registered criteria)

    Led by Union HospitalWuhan

  161. Not yet recruiting
    A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2025-02
    Registry
    NCT06799676

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesWuhan, Zhengzhou

  162. Not yet recruiting
    A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2025-04
    Registry
    NCT06895512

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  163. Not yet recruiting
    Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06963866

    Age 18 years to 70 years (registered criteria)

    Led by Affiliated Hospital of Xuzhou Medical UniversityXuzhou

  164. Not yet recruiting
    Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma
    Phase
    N/A
    Started
    2025-07
    Registry
    NCT07034755

    Age 18 years to 70 years (registered criteria)

    Led by Affiliated Hospital of Xuzhou Medical UniversityXuzhou

  165. Not yet recruiting
    Risk-adapted Therapeutic Strategy in +1q NDMM
    Phase
    Not given
    Started
    2025-09
    Registry
    NCT07045168

    Age not stated (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  166. Not yet recruiting
    A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2025-08
    Registry
    NCT07090954

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Xi'an

  167. Not yet recruiting
    RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07113496

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  168. Not yet recruiting
    RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07114432

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  169. Not yet recruiting
    Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients
    Phase
    Phase 3
    Started
    2025-09
    Registry
    NCT07181239

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  170. Not yet recruiting
    ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab
    Phase
    Not given
    Started
    2025-12
    Registry
    NCT07320326

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  171. Not yet recruiting
    To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma
    Phase
    Early phase 1
    Started
    2024-03
    Registry
    NCT06298266

    Age 18 years to 75 years (registered criteria)

    Led by Guangdong Second Provincial General HospitalGuangzhou

  172. Not yet recruiting
    A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.
    Phase
    Not given
    Started
    2024-06
    Registry
    NCT06369935

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  173. Not yet recruiting
    LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma
    Phase
    N/A
    Started
    2024-07
    Registry
    NCT06472479

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province Hospital; 2 listed hospitals as study sitesHefei, Nanjing, Zhengzhou

  174. Not yet recruiting
    A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2024-08
    Registry
    NCT06500507

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  175. Not yet recruiting
    Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma
    Phase
    N/A
    Started
    2024-10
    Registry
    NCT06594211

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  176. Not yet recruiting
    A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)
    Phase
    Phase 1
    Started
    2022-04
    Registry
    NCT05181501

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChangzhou, Hefei, Nanjing

  177. Not yet recruiting
    A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
    Phase
    Early phase 1
    Started
    2021-01
    Registry
    NCT04670055

    Age 30 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  178. Not yet recruiting
    A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy
    Phase
    Early phase 1
    Started
    2020-12
    Registry
    NCT04541368

    Age 30 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  179. Enrolling by invitation
    Long-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F Injection
    Phase
    Not given
    Started
    2026-11
    Registry
    NCT07833046

    Age not stated (registered criteria)

    Led by Renji HospitalShanghai

  180. Enrolling by invitation
    AI-Based Fine Morphological Subtyping of Myeloma Single Cells for Predicting FISH Abnormalities
    Phase
    Not given
    Started
    2018-08
    Registry
    NCT07410403

    Age not stated (registered criteria)

    Led by Zhongnan Hospital of Wuhan UniversityWuhan

  181. Enrolling by invitation
    Autologous Stem Cell Transplantation for Patients With AL Amyloidosis
    Phase
    Not given
    Started
    2010-07
    Registry
    NCT04210791

    Age 18 years to 75 years (registered criteria)

    Led by Jinling HospitalNanjing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Additional research sources

Read the linked papers and reports

Before contacting a hospital

The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.

Where these numbers come from

Papers

1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search

Trials

ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 8 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data (CSV)Definitions